CN106729705B - 一种药物组合物及其应用 - Google Patents
一种药物组合物及其应用 Download PDFInfo
- Publication number
- CN106729705B CN106729705B CN201710050114.0A CN201710050114A CN106729705B CN 106729705 B CN106729705 B CN 106729705B CN 201710050114 A CN201710050114 A CN 201710050114A CN 106729705 B CN106729705 B CN 106729705B
- Authority
- CN
- China
- Prior art keywords
- cell
- specific amplification
- antibody
- pharmaceutical composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 60
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 50
- 230000003321 amplification Effects 0.000 claims abstract description 40
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 40
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 33
- 230000004913 activation Effects 0.000 claims abstract description 32
- 210000003734 kidney Anatomy 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 38
- 238000005119 centrifugation Methods 0.000 claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 229930182566 Gentamicin Natural products 0.000 claims description 6
- 102100037850 Interferon gamma Human genes 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 6
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 239000012267 brine Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 5
- 102100027211 Albumin Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 229960002518 gentamicin Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- -1 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 62
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract description 33
- 206010038389 Renal cancer Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 21
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 18
- 201000010982 kidney cancer Diseases 0.000 abstract description 18
- 206010067484 Adverse reaction Diseases 0.000 abstract description 11
- 230000006838 adverse reaction Effects 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 238000011156 evaluation Methods 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 230000001665 lethal effect Effects 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001202 rhombencephalon Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 201000010174 renal carcinoma Diseases 0.000 description 4
- 108010056030 retronectin Proteins 0.000 description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010048612 Hydrothorax Diseases 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000002758 humerus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000012309 immunohistochemistry technique Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000002719 stereotactic radiosurgery Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims (4)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710050114.0A CN106729705B (zh) | 2017-01-23 | 2017-01-23 | 一种药物组合物及其应用 |
US16/092,678 US20190160099A1 (en) | 2017-01-23 | 2017-03-15 | Pharmaceutical composition and use thereof |
PCT/CN2017/076684 WO2018133187A1 (zh) | 2017-01-23 | 2017-03-15 | 一种药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710050114.0A CN106729705B (zh) | 2017-01-23 | 2017-01-23 | 一种药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106729705A CN106729705A (zh) | 2017-05-31 |
CN106729705B true CN106729705B (zh) | 2018-04-06 |
Family
ID=58942466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710050114.0A Active CN106729705B (zh) | 2017-01-23 | 2017-01-23 | 一种药物组合物及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20190160099A1 (zh) |
CN (1) | CN106729705B (zh) |
WO (1) | WO2018133187A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796483A (zh) * | 2022-06-28 | 2022-07-29 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
CN113244383B (zh) * | 2021-06-11 | 2021-09-10 | 诺赛联合(北京)生物医学科技有限公司 | 一种dc瘤苗制备方法及其在肿瘤治疗中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104357394A (zh) * | 2014-10-24 | 2015-02-18 | 杭州阿德莱诺泰制药技术有限公司 | 一种自体外周血淋巴细胞dc-cik的培养方法 |
CN104371974A (zh) * | 2014-10-24 | 2015-02-25 | 杭州阿德莱诺泰制药技术有限公司 | 一种自体外周血淋巴细胞cik的培养方法 |
CN105219711A (zh) * | 2014-06-05 | 2016-01-06 | 深圳市金佳禾生物医药有限公司 | 一种CIKs细胞和DC-CIKs细胞的培养体系 |
CN105695406A (zh) * | 2016-04-27 | 2016-06-22 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性dc-cik免疫细胞的方法及制得的dc-cik免疫细胞 |
CN105861433A (zh) * | 2016-04-27 | 2016-08-17 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 |
CN106777931A (zh) * | 2016-12-01 | 2017-05-31 | 广东技术师范学院 | 一种不同主体对不同客体的评价方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102839153A (zh) * | 2012-09-13 | 2012-12-26 | 济南泰生生物技术有限公司 | 一种以cd3+cd8+为主的活化淋巴细胞的扩增、冻存及复苏方法 |
CN103667189B (zh) * | 2013-09-24 | 2015-10-28 | 上海宇研生物技术有限公司 | 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法 |
US20170088626A1 (en) * | 2014-03-05 | 2017-03-30 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
-
2017
- 2017-01-23 CN CN201710050114.0A patent/CN106729705B/zh active Active
- 2017-03-15 US US16/092,678 patent/US20190160099A1/en not_active Abandoned
- 2017-03-15 WO PCT/CN2017/076684 patent/WO2018133187A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105219711A (zh) * | 2014-06-05 | 2016-01-06 | 深圳市金佳禾生物医药有限公司 | 一种CIKs细胞和DC-CIKs细胞的培养体系 |
CN104357394A (zh) * | 2014-10-24 | 2015-02-18 | 杭州阿德莱诺泰制药技术有限公司 | 一种自体外周血淋巴细胞dc-cik的培养方法 |
CN104371974A (zh) * | 2014-10-24 | 2015-02-25 | 杭州阿德莱诺泰制药技术有限公司 | 一种自体外周血淋巴细胞cik的培养方法 |
CN105695406A (zh) * | 2016-04-27 | 2016-06-22 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性dc-cik免疫细胞的方法及制得的dc-cik免疫细胞 |
CN105861433A (zh) * | 2016-04-27 | 2016-08-17 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 |
CN106777931A (zh) * | 2016-12-01 | 2017-05-31 | 广东技术师范学院 | 一种不同主体对不同客体的评价方法 |
Non-Patent Citations (2)
Title |
---|
Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts;Poh等;《CANCER IMMUNOLOGY IMMUNOTHERAPY》;20160310;第65卷(第5期);第525-536页 * |
Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer;Dai等;《oncotarget》;20160228;第7卷(第9期);第10332-10344页 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796483A (zh) * | 2022-06-28 | 2022-07-29 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
CN114796483B (zh) * | 2022-06-28 | 2022-11-08 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
Also Published As
Publication number | Publication date |
---|---|
US20190160099A1 (en) | 2019-05-30 |
WO2018133187A1 (zh) | 2018-07-26 |
CN106729705A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chajon et al. | The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership | |
Ayodele et al. | Immunotherapy in soft-tissue sarcoma | |
Frampton | Mifamurtide: a review of its use in the treatment of osteosarcoma | |
Schwartzberg | Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma | |
Bonanni et al. | Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells | |
CN106729705B (zh) | 一种药物组合物及其应用 | |
Eiling et al. | Schnitzler syndrome: treatment failure to rituximab but response to anakinra | |
Tabchi et al. | Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab | |
CN108136025A (zh) | 一种使用免疫调节治疗癌症的新颖方法 | |
KR20170015460A (ko) | 방사선 치료와 조합된 pd-1 및 pd-l1에 대한 길항제를 이용하는 암 치료 방법 | |
Starling et al. | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer | |
Engel-Riedel et al. | A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer | |
CN106890330A (zh) | Dc‑cik细胞和抗pd‑1抗体组合物及其用途 | |
Broccoli et al. | Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports | |
Yue et al. | Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial | |
Sharon et al. | Immunotherapy in head and neck squamous cell carcinoma: a narrative review | |
Zhong et al. | Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors | |
Talpur et al. | A single-center experience with brentuximab vedotin in gamma delta T-cell lymphoma | |
CN108472352A (zh) | 用于癌症治疗的细菌菌蜕 | |
Maleki et al. | P864 Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients | |
Hirte et al. | Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody | |
CN105969731A (zh) | 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法 | |
CN108815188A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
WO2023210042A1 (ja) | Il-34を発現する腫瘍を治療および/または予防するための医薬 | |
EP2402034B1 (en) | A method for screening for a substance having an action of proliferating natural killer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Gao Quanli Inventor after: Xu Benling Inventor after: Song Yongping Inventor after: Zhao Lingdi Inventor after: Wang Zibing Inventor before: Gao Quanli Inventor before: Wei Dan |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180211 Address after: Torch high tech Zone Park No. 1789 in Xinxiang city of Henan province Frestech Avenue 453000 Applicant after: HENAN HUALONG BIOLOGICAL TECHNOLOGY CO., LTD. Applicant after: Henan Prov. Tumour Hospital Address before: Torch high tech Zone Park No. 1789 in Xinxiang city of Henan province Frestech Avenue 453000 Applicant before: HENAN HUALONG BIOLOGICAL TECHNOLOGY CO., LTD. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |